Thursday, May 28, 2015 8:02:58 AM
Well if goes to $2 I'll accumulate. I already have bids in. I understand all you say and these companies are deceiving. I feel your frustration. The other company I almost bought other day I felt was too"volatile" and may go down %5 or more here and there lol and is,an OTC. It went up 90% yesterday! I bought this company last week thinking it be more safe and stable ha! Boy what a joke these companies. All stocks. I'm new to company. And focusing on biotech stocks now. So any info you have is greatly appreciated. I too believe in their science and that they have something very good and that can help so many someday. And be worth billions even perhaps. But unfortunately these companies need to finance very very expensive trials before they make it big and hit billions and fame. No ones going to sell for less than the offering or at it unless idiots. I think people are panicking at these low prices. But who knows. I'm going to double down while cheap here. I'm new to stock as of last week I know it can have or will soon have huge success. These are the times you accumulate. As for the reverse. I was in a pharmaceutical that after I had just been confirmed by CEO all was great and share structure would go through positive changes etc few minutes later a reverse split was announced and I lost most my money. .thousands gone in minutes. These companies and ceos are money hungry deceiving thieves doing all they can get away with legally in the corrupt stock market I'm getting fed up with. I believe this to be a great company with great product but going overboard to get price up before underwriter public offering completed. Phase 3 will be the big trigger setting stock off into huge success and a very amazing future of cancer treatments and growth. Let the company do what it has to ignite this phase 3 and get this treatment out. NBS looks to truly be a very impressive and so far very successful biotech doing amazing things.
Recent LSTA News
- Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. • GlobeNewswire Inc. • 03/06/2026 11:15:05 PM
- Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide • GlobeNewswire Inc. • 01/27/2026 01:00:00 PM
- All-Cash Buyout Sparks Breakout Move in Biotech Name • AllPennyStocks.com • 01/21/2026 04:14:37 PM
- Lisata Therapeutics surges on Kuva Labs takeover proposal carrying hefty premium • IH Market News • 01/21/2026 03:41:11 PM
- Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer • GlobeNewswire Inc. • 01/21/2026 12:00:00 PM
- Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/06/2025 09:05:00 PM
- Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’ • GlobeNewswire Inc. • 11/06/2025 01:00:00 PM
- Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent • GlobeNewswire Inc. • 11/04/2025 09:00:00 PM
- Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025 • GlobeNewswire Inc. • 10/30/2025 12:00:00 PM
- Lisata Therapeutics to Present at LD Micro Main Event XIX • Newsfile • 10/13/2025 12:00:00 PM
- Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement • GlobeNewswire Inc. • 10/08/2025 12:30:00 PM
- Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial • GlobeNewswire Inc. • 09/29/2025 12:00:00 PM
- Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference • GlobeNewswire Inc. • 09/02/2025 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2025 08:13:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2025 08:09:29 PM
- Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/07/2025 08:05:00 PM
- Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025 • GlobeNewswire Inc. • 07/31/2025 12:00:00 PM
- Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update • GlobeNewswire Inc. • 07/17/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2025 12:00:44 PM
- Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide • GlobeNewswire Inc. • 07/15/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/26/2025 12:38:40 PM
- Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer • GlobeNewswire Inc. • 06/26/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2025 01:13:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2025 08:02:11 PM
- Lisata Therapeutics to Present at the 2025 BIO International Convention • GlobeNewswire Inc. • 06/11/2025 12:30:00 PM
